890170-93-1

Basic information

• Product Name: ethyl 4-(2-chloroethyl)benzoate
• Synonyms: ethyl 4-(2-chloroethyl)benzoate
• CAS NO: 890170-93-1
• Molecular Weight: 212.676
• Mol File: 890170-93-1.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: ethyl 4-(2-chloroethyl)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-(2-chloroethyl)benzoate(890170-93-1)
• EPA Substance Registry System: ethyl 4-(2-chloroethyl)benzoate(890170-93-1)

Safety Data

• Hazardous Substances Data: 890170-93-1(Hazardous Substances Data)

Upstream product

• 64-17-5 ethanol 
• 20849-78-9 p-(beta-chloroethyl)benzoic acid 
• 52798-01-3 methyl 4-cyanobenzeneacetate 
• 69395-13-7 4-(2-hydroxyethyl)benzonitrile 
• 46112-46-3 4-(2-((tert-butyldimethylsilyl)oxy)ethyl)benzoic acid 
• 78254-55-4 ethyl 4-(2-hydroxyethyl)benzoate 
• 41841-16-1 (4-bromo-phenyl)-acetic acid methyl ester 

Downstream Products

• 956901-49-8 C₂₂H₂₆O₄S₂ 
• 890170-95-3 ethyl 4-(2-mercaptoethyl)benzoate 
• 1207340-08-6 ethyl 4-[2-[4-[[(2-ethyl-2H-pyrrolo[3,4-c]-4-quinolinyl)oxy]-methyl]-1-piperidinyl]ethyl]benzoate 
• 890170-94-2 ethyl 4-(2-acetylsulfanylethyl)benzoate 

Relevant articles and documents

Selective A2A receptor antagonist

The invention provides a selective A2A receptor antagonist. In specific, the invention provides the selective A2A receptor antagonist shown in the formula (I), a drug composition containing the same and the pharmacy application and treatment application t

COMPOUND WITH SEROTONINERGIC ACTIVITY, PROCESS FOR PREPARING IT AND PHARMACEUTICAL COMPOSITION COMPRISING IT

Compound of formula (I) in which R1, R2 and R3 are defined in the following description, and the pharmaceutically acceptable acid-addition or base-addition salts thereof. The invention also relates to a process and an intermediate for preparing it, and to a pharmaceutical composition comprising it. The invention also relates to the use of a novel 2H-pyrrolo[3,4-c]quinoline compound for preparing a pharmaceutical composition that is active in the treatment of disturbances of the serotoninergic system.